论文部分内容阅读
目的探讨化疗联合尿多酸肽注射液(CDA-Ⅱ)在晚期复治非小细胞肺癌(NSCLC)治疗中的应用价值。方法 108例NSCLC患者,随机分成观察组和对照组,各54例。两组均给予化疗治疗,观察组在化疗基础上联合CDA-Ⅱ治疗。比较观察两组临床疗效、远期生存率、不良反应发生情况。结果观察组治疗总有效率为72.22%、远期生存率为57.41%,均高于对照组的42.59%、29.63%,差异均具有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论晚期复治NSCLC,通过化疗联合CDA-Ⅱ治疗,临床效果较佳,且能提高患者的远期生存率,降低不良反应发生率。
Objective To investigate the value of chemotherapy combined with uroacitide injection (CDA-Ⅱ) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods 108 cases of NSCLC patients were randomly divided into observation group and control group, each 54 cases. Two groups were given chemotherapy, the observation group on the basis of chemotherapy combined with CDA-Ⅱ treatment. The clinical efficacy, long-term survival rate and adverse reactions of the two groups were compared. Results The total effective rate of observation group was 72.22%, long-term survival rate was 57.41%, which was higher than that of control group (42.59%, 29.63%), the differences were statistically significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusions The treatment of advanced NSCLC with advanced chemotherapeutic agents combined with CDA-Ⅱ has better clinical effect and can improve the long-term survival rate and reduce the incidence of adverse reactions.